The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Peter Nash
Alvin WellsAt the European Alliance of Associations for Rheumatology (EULAR) Congress 2024, our steering committee member Peter Nash, Griffith University, Queensland, AU, interviewed Alvin Wells, a rheumatologist in Chicago and Milwaukee, US, about new and emerging therapies for psoriatic arthritis (PsA).
New and emerging therapies for psoriatic arthritis
Wells discusses how therapy options have improved over recent years, with the introduction of interleukin (IL), Janus kinase (JAK), and tyrosine kinase 2 (TYK2) inhibitors. He also speaks about the use of JAK inhibitors in PsA, their approvals, and how he uses these in his practice. Finally, Wells talks about the potential of chimeric antigen receptor (CAR) T-cell therapies in PsA.